Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells $174,880.80 in Stock

Key Points

• Mario Alberto Accardi sold 8,172 shares of Centessa Pharmaceuticals at an average price of $21.40, resulting in a total transaction of $174,880.80, and now holds 197,394 shares valued at approximately $4.22 million.
• Centessa Pharmaceuticals' stock recently traded down to $21.33, with a 52-week low of $9.60 and a high of $23.24, while its average target price from analysts is $32.44.
• Several institutional investors have significantly increased their stakes in Centessa, with 82.01% of the company's stock now owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Mario Alberto Accardi sold 8,172 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total transaction of $174,880.80. Following the completion of the sale, the insider directly owned 197,394 shares in the company, valued at approximately $4,224,231.60. This trade represents a 3.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Mario Alberto Accardi also recently made the following trade(s):

• On Tuesday, September 9th, Mario Alberto Accardi sold 7,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $20.00, for a total transaction of $140,000.00.
• On Tuesday, July 29th, Mario Alberto Accardi sold 8,322 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.23, for a total transaction of $126,744.06.
• On Tuesday, June 24th, Mario Alberto Accardi sold 15,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $14.00, for a total value of $210,000.00.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA traded down $0.18 during midday trading on Friday, hitting $22.79. 783,013 shares of the company's stock were exchanged, compared to its average volume of 1,431,530. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $9.60 and a twelve month high of $23.51. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12. The firm has a market cap of $3.05 billion, a P/E ratio of -12.73 and a beta of 1.47. The stock's 50 day moving average price is $17.55 and its 200-day moving average price is $14.85.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Equities research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CNTA. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an "outperform" rating and a $40.00 price objective on the stock. Wells Fargo & Company assumed coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, September 3rd. They set an "overweight" rating and a $31.00 price target on the stock. Needham & Company LLC assumed coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price target for the company. Wall Street Zen lowered shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Finally, Truist Financial assumed coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $32.38.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. boosted its position in shares of Centessa Pharmaceuticals by 20.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company's stock worth $110,415,000 after buying an additional 1,449,000 shares during the period. Commodore Capital LP lifted its stake in Centessa Pharmaceuticals by 39.3% in the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company's stock worth $43,340,000 after acquiring an additional 930,711 shares in the last quarter. Affinity Asset Advisors LLC boosted its position in Centessa Pharmaceuticals by 41.1% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,546,662 shares of the company's stock worth $22,241,000 after acquiring an additional 450,738 shares during the period. Stempoint Capital LP grew its stake in Centessa Pharmaceuticals by 113.3% during the 2nd quarter. Stempoint Capital LP now owns 1,265,672 shares of the company's stock valued at $16,631,000 after acquiring an additional 672,337 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in Centessa Pharmaceuticals during the 2nd quarter valued at about $16,052,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.